SHANGHAI, June 30, 2022 /PRNewswire/ Eurofins DiscoverX (Eurofins DiscoverX Products LLC), a global industry leader of products for small and large molecule drug discovery and QC lot release, today announced the official opening of its new China biotechnology office in Shanghai. The launch of Eurofins DiscoverX (Shanghai) Ltd. broadens its Asia-Pacific operations directly into the China market. This expansion establishes an operational base positioned to effectively serve China's growing biopharmaceutical sector with high-quality innovative products that accelerate drug discovery programs, contributing to improving global healthcare. With this fully operational Shanghai office, Eurofins DiscoverX can more readily provide its product menu cell lines, assay reagents, enzymes and bioassay kits to the China market. The new Shanghai operation provides an efficient supply chain, local technical support, and the convenience for clients to pay in the Chinese Yuan (RMB) currency. This ope
/PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery,.
ST. CHARLES, Mo., June 23, 2022 /PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery
ST. CHARLES, Mo., June 24, 2022 /PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, announces a client publication advancing cognitive health research through use of the company's BioMAP Human Phenotypic Profiling and Screening Platform and enzyme assays for neurotransmitter degradation. Published in BMC Complementary Medicine and Therapies, the work of scientists from The Institute for Biomedical and Bioscience Research, University of Buckingham; the European Genomic Institute for Diabetes, Hospital Claude Huriez; and Sibelius Ltd., identifies changes in biomarkers of inflammation and tissue remodeling that result from the use of sage extract on in vitro, human primary cell translational disease models. The work documents applicability of the BioMAP Platform beyond standard biopharmaceutical applications and demonstrates the portfolio breadth of Eurofins Discovery in providing
ST. CHARLES, Mo., June 24, 2022 /PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, announces a client publication advancing cognitive health research through use of the company's BioMAP Human Phenotypic Profiling and Screening Platform and enzyme assays for neurotransmitter degradation. Published in BMC Complementary Medicine and Therapies, the work of scientists from The Institute for Biomedical and Bioscience Research, University of Buckingham; the European Genomic Institute for Diabetes, Hospital Claude Huriez; and Sibelius Ltd., identifies changes in biomarkers of inflammation and tissue remodeling that result from the use of sage extract on in vitro, human primary cell translational disease models. The work documents applicability of the BioMAP Platform beyond standard biopharmaceutical applications and demonstrates the portfolio breadth of Eurofins Discovery in providing